Welcome to our dedicated page for Vericel news (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel stock.
Vericel Corporation (VCEL) pioneers patient-specific cellular therapies for sports medicine and severe burn care through advanced regenerative science. This dedicated news hub provides investors and medical professionals with timely updates on the company’s progress in transforming treatment paradigms.
Access authoritative information on FDA approvals, clinical trial outcomes, and strategic initiatives shaping the future of cell-based therapies. Our curated collection includes:
- Quarterly earnings reports and financial disclosures
- Product launch announcements and manufacturing updates
- Research collaborations and intellectual property developments
- Regulatory milestones for novel treatment platforms
Bookmark this page for streamlined tracking of Vericel’s advancements in autologous cell therapies, including innovations in cartilage repair and burn wound management. Stay informed about developments that impact both patient care and investment considerations in the evolving biologics sector.
Vericel (NASDAQ:VCEL) has announced that the FDA has approved NexoBrid® (anacaulase-bcdb) for eschar removal in pediatric patients with deep partial-thickness and/or full-thickness thermal burns. This approval expands NexoBrid's target customer base to include approximately 20 pediatric burn centers in the United States. The approval is based on results from the global Phase 3 CIDS trial and additional pediatric data from Phase 3 and Phase 2 studies. NexoBrid offers a non-surgical solution for managing severe burn injuries in pediatric patients, providing a less invasive alternative to traditional methods. The company expects this expansion to have a meaningful impact on overall NexoBrid uptake over time.
Vericel (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care, has announced its participation in the Canaccord Genuity Growth Conference. Nick Colangelo, the company's President and CEO, is scheduled to present on Wednesday, August 14, 2024, at 3:00 p.m. ET.
This presentation offers an opportunity for investors and interested parties to gain insights into Vericel's operations and growth strategies. The company has made the event accessible to a wider audience by providing a webcast of the presentation, which will be available on the Investor Relations section of Vericel's official website at http://investors.vcel.com.
Vericel's participation in this conference underscores its commitment to transparency and engagement with the investment community, potentially impacting its market position and investor relations.
Vericel (NASDAQ:VCEL) reported strong Q2 2024 financial results, with total revenue of $52.7 million, a 15% increase year-over-year. MACI revenue grew 21% to $44.1 million, while Burn Care revenue reached $8.5 million. The company achieved a gross margin of 70%, up 430 basis points, and adjusted EBITDA increased 42% to $6.3 million. Vericel raised its full-year profitability guidance to 71% gross margin and 21% adjusted EBITDA margin. The company maintains a strong financial position with $154 million in cash and no debt. Key highlights include record Q2 total revenue, progress in NexoBrid launch, and anticipated MACI Arthro launch later this quarter.
Vericel (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care, has appointed Karen Mahoney as Chief Human Resources Officer. This follows the retirement of Heidi Hassen, who served in the role since 2010. Mahoney brings over 20 years of experience in life sciences and medical devices, most recently as CHRO at Abiomed. Her expertise includes HR strategy, talent selection, and leadership development.
Mahoney's appointment is expected to drive organizational success and support Vericel's long-term growth. She aims to foster a purpose-driven, patient-focused culture that attracts top talent. Nick Colangelo, Vericel's President and CEO, expressed confidence in Mahoney's ability to contribute to the company's continued success.
Vericel (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care markets, has announced it will report its second-quarter 2024 financial results on Thursday, August 1, 2024. The company's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss financial results and business highlights.
Investors can access the live webcast on Vericel's Investor Relations website. Participants are advised to register at least 15 minutes before the scheduled start time. For those joining by telephone, registration is required to receive dial-in details and a personal passcode. Presentation slides will be available on the webcast and Investor Relations section. A replay of the webcast will be accessible on Vericel's website until August 1, 2025.
Vericel (NASDAQ: VCEL), a prominent player in sports medicine and severe burn care, announced its participation in the Truist Securities MedTech Conference. The event will feature a fireside chat with President and CEO Nick Colangelo, along with CFO Joe Mara, scheduled for 2:30 p.m. ET on June 18, 2024. Investors and interested parties can access the webcast through Vericel's Investor Relations website.
Vericel (NASDAQ:VCEL), a key player in advanced therapies for sports medicine and severe burn care, announced its participation in the Leerink Partners Healthcare Crossroads Conference. The event will take place on May 29, 2024, at 9:40 a.m. ET. Vericel's President and CEO, Nick Colangelo, along with CFO Joe Mara, will represent the company in a fireside chat. Investors and interested parties can access the webcast of the presentation through the Investor Relations section of the Vericel website.
Vericel (NASDAQ:VCEL) reported a 25% increase in total revenue to $51.3 million in the first quarter of 2024. The company achieved record revenue for MACI of $40.2 million and saw a 63% growth in Burn Care revenue. Adjusted EBITDA grew by 325%. The full-year 2024 revenue guidance was raised to $238-$242 million. Vericel had a strong start to the year with significant margin expansion and profitability growth, positioning the company well for continued growth. The company also reported positive progress in new product launches and market penetration.
FAQ
What is the current stock price of Vericel (VCEL)?
What is the market cap of Vericel (VCEL)?
